Mai Badarni

Mai Badarni

Auto-generated profile, based on publicly available information

Mai Badarni

The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SJSANKAR JAGADEESHAN
SANKAR JAGADEESHAN
MPManu Prasad
Manu Prasad
MBMai Badarni
Mai Badarni
TBTalal Ben-Lulu
Talal Ben-Lulu
VLVijayasteltar B Liju
Vijayasteltar B Liju
MEMoshe Elkabets
Moshe Elkabets
The survival rate for patients with head and neck cancer (HNC) diagnosed with cervical lymph node (cLN) or distant metastasis is low. Genomic alterations in the HRAS oncogene are associated with advanced tumor stage and metastasis in HNC. Elucidation of the molecular mechanisms by which mutated HRAS (HRASmut) facilitates HNC metastasis could lead to improved treatment options for patients. Here, we examined metastasis driven by mutant HRAS in vitro and in vivo using HRASmut human HNC cell lines, patient-derived xenografts, and a novel HRASmut syngeneic model. Genetic and pharmacological manipulations indicated that HRASmut was sufficient to drive invasion in vitro and metastasis in vivo. Targeted proteomic analysis showed that HRASmut promoted AXL expression via suppressing the Hippo pathway and stabilizing YAP1 activity. Pharmacological blockade of HRAS signaling with the farnesyltransferase inhibitor tipifarnib activated the Hippo pathway and reduced the nuclear export of YAP1, thus suppressing YAP1-mediated AXL expression and metastasis. AXL was required for HRASmut cells to migrate and invade in vitro and to form regional cLN and lung metastases in vivo. In addition, AXL-depleted HRASmut tumors displayed reduced lymphatic and vascular angiogenesis in the primary tumor. Tipifarnib treatment also regulated AXL expression and attenuated VEGFA and VEGFC expression, thus regulating tumor-induced vascular formation and metastasis. Our results indicate that YAP1 and AXL are crucial factors for HRASmut-induced metastasis and that tipifarnib treatment can limit the metastasis of HNC tumors with HRAS mutations by enhancing YAP1 cytoplasmic sequestration and downregulating AXL expression. Significance: Mutant HRAS drives metastasis of head and neck cancer by switching off the Hippo pathway to activate the YAP1–AXL axis and to stimulate lymphovascular angiogenesis.

22 August 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
MPManu Prasad
Manu Prasad
JZJonathan Zorea
Jonathan Zorea
SJSANKAR JAGADEESHAN
SANKAR JAGADEESHAN
ASAvital Shnerb
Avital Shnerb
JBJebrane Bouaoud
Jebrane Bouaoud
MEMoshe Elkabets
Moshe Elkabets
Although the mitogen-activated protein kinases (MAPK) pathway is hyperactive in head and neck cancer (HNC), inhibition of MEK1/2 in HNC patients has not shown clinically meaningful activity. Using pre-clinical HNC models, we demonstrated that treatment with the MEK1/2 blocker trametinib delays HNC initiation and progression by reducing tumor cell proliferation and enhancing the anti-tumor immunity of CD8 + T cells. Further activation of CD8 + T cells by supplementation with anti-programmed death-1 (αPD-1) antibody eliminated tumors and induced an immune memory in the cured mice. Mechanistically, an early response to trametinib treatment sensitized tumors to αPD-1-supplementation by attenuating the expression of tumor-derived colony-stimulating factor-1 (CSF-1), which reduced the abundance of two CSF-1R + CD11c + myeloid-derived suppressor cell (MDSC) populations in the tumor microenvironment (TME). In contrast, prolonged treatment with trametinib abolished the anti-tumor activity of αPD-1, because tumor cells undergoing the epithelial to mesenchymal transition (EMT) in response to trametinib restored CSF-1 expression and re-created an immune-suppressive TME. These findings provide the rationale for testing the trametinib/αPD-1 combination in HNC and highlight the importance of sensitizing tumors to immunotherapies by using targeted therapies to interfere with the host-tumor interaction. Graphical

4 April 2023
Verified
Other
Open access
SJSANKAR JAGADEESHAN
SANKAR JAGADEESHAN
MPManu Prasad
Manu Prasad
MBMai Badarni
Mai Badarni
TBTalal Ben-Lulu
Talal Ben-Lulu
VLVijayasteltar B Liju
Vijayasteltar B Liju
MEMoshe Elkabets
Moshe Elkabets
Supplementary Materials and Methods

16 September 2024
Verified
Other
Open access
SJSANKAR JAGADEESHAN
SANKAR JAGADEESHAN
MPManu Prasad
Manu Prasad
MBMai Badarni
Mai Badarni
TLTalal Ben Lulu
Talal Ben Lulu
VLVijayasteltar B Liju
Vijayasteltar B Liju
MEMoshe Elkabets
Moshe Elkabets
Supplementary Materials and Methods

4 April 2023
Verified
Other
Open access
SJSANKAR JAGADEESHAN
SANKAR JAGADEESHAN
MPManu Prasad
Manu Prasad
MBMai Badarni
Mai Badarni
TBTalal Ben-Lulu
Talal Ben-Lulu
VLVijayasteltar B Liju
Vijayasteltar B Liju
MEMoshe Elkabets
Moshe Elkabets
Supplementary Materials and Methods

4 April 2023
Verified
Other
Open access
SJSANKAR JAGADEESHAN
SANKAR JAGADEESHAN
MPManu Prasad
Manu Prasad
MBMai Badarni
Mai Badarni
TBTalal Ben-Lulu
Talal Ben-Lulu
VLVijayasteltar B Liju
Vijayasteltar B Liju
MEMoshe Elkabets
Moshe Elkabets
Supplementary Figures S1 to S6 with figure legends